Indivumed Therapeutics
Dr. rer. nat. Frauke Degenhardt is a Data Scientist at Indivumed Group since August 2022, specializing in therapeutic target discovery and multi-OMICs analysis in cancer through classical statistical and machine learning techniques. Previously, Dr. Degenhardt served as a Postdoctoral Researcher at the Institute of Clinical Molecular Biology from August 2013 to August 2022, focusing on statistical analysis of COVID-19 genetics and HLA genetics across various disease contexts, while coordinating projects within the Severe COVID-19 GWAS consortium. Dr. Degenhardt also has experience as a Doctoral Student, emphasizing clinical and multi-OMICs data analysis, and has engaged in pipeline design for HLA imputation. Academic qualifications include a Doctor of Science in Computational Biology from Kiel University, a Master's degree in Computational Life Science from Universität zu Lübeck, and a Bachelor's degree in Molecular Life Science from the same institution.